Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.3552W HIGH $46.75
Volume
625.76 K
Value Traded
2.36 M
Short % Float
39.12%
+1.53%Week
-22.78%1 Month
-30.31%3 Month
-62.15%6 Month
-95.12%5 Year
-95.12%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
114.53 M
EPS (TTM)
-4.01
P/E Ratio
-
Ent. Value
-105.48 M
Total Shares
31.42 M
Float Shares
27.17 M
Insiders
13.51%
Institutions
102.04%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LENZ Catalyst Timeline
Dated clinical, regulatory and corporate events for LENZ Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for LENZ Therapeutics, Inc.
204Total events
1Upcoming
60Tier-1 (high impact)
2021 to 2027Coverage
Event history 50
▲Product LaunchVIZZApprovedPost-Market
Launch of telehealth prescribing option for VIZZ
presbyopiasource ↗
●Other Regulator MilestoneVIZZApprovedEx-US Regulatory
MAA submitted under Saudi FDA Abridged Pathway for VIZZ
presbyopiasource ↗
▲Product LaunchVIZZApprovedPost-Market
Launch of nationwide TV advertising campaign for VIZZ
presbyopiasource ↗
▲Partnership / LicenseVIZZApprovedCorporate
Exclusive license and commercialization agreement with Arrotex for VIZZ in Australia and New Zealand
presbyopiasource ↗
▲Partnership / LicenseVIZZApprovedCorporate
Everest Medicines acquires rights to develop and commercialize VIZZ (LNZ100) in Greater China
presbyopiasource ↗
▲Partnership / LicenseVIZZApprovedCorporate
Exclusive license and commercialization agreement with Arrotex Pharmaceuticals for Australia and New Zealand
presbyopiasource ↗
●Other Regulator MilestoneVIZZApprovedEx-US Regulatory
New Drug Submission to Health Canada for VIZZ
presbyopiasource ↗
▲Milestone PaymentVIZZApprovedCorporate
Received $1.25 million sublicense revenue from Everest/CORXEL
presbyopiasource ↗
◆Quarterly UpdateCorporate
First Quarter 2026 Financial Results and Recent Corporate Highlights Webcast
●Timing GuidancePresentation
DTC campaign expansion into network television advertising in select markets in early Q2 2026
▲Quarterly UpdateCorporate
Pilot expansion of DTC campaign into network and cable television advertising
●Oral PresentationPresentation
Conference call and webcast to discuss Q4 and full year 2025 results
◆Oral PresentationPresentation
Leerink Partners 2026 Global Healthcare Conference fireside chat
▲Product LaunchVIZZApprovedPost-Market
VIZZ consumer campaign launch with Sarah Jessica Parker
presbyopiasource ↗
▲Quarterly UpdateCorporate
Q4 2025 preliminary unaudited financial results: ~$1.6M net product revenue, >20,000 prescriptions filled
▲Partnership / LicenseVIZZApprovedCorporate
Exclusive commercialization partnership with Lunatus for VIZZ in the Middle East
presbyopiasource ↗
▲Partnership / LicenseVIZZApprovedCorporate
Exclusive distribution agreement with Lunatus for Middle East
presbyopiasource ↗
◆Timing GuidanceVIZZApprovedPresentation
DTC campaign launch anticipated in Q1 2026
presbyopiasource ↗
●NDA SubmissionVIZZApprovedRegulatory Filing
NDA submissions in Thailand and Singapore
presbyopiasource ↗
▲Quarterly UpdateCorporate
Launched 'Tired of Reading Glasses' DTC campaign featuring Sarah Jessica Parker
▼Serious Ae Or DeathVIZZApprovedSafety
Retinal tear associated with VIZZ eye drop reported in FDA adverse event system
ophthalmicsource ↗
●Other Regulator MilestoneVIZZApprovedEx-US Regulatory
MFDS NDA submission for VIZZ in South Korea
presbyopiasource ↗
▲Partnership / LicenseVIZZApprovedCorporate
Partnered with Sarah Jessica Parker as DTC campaign spokesperson
presbyopiasource ↗
◆Poster PresentationVIZZApprovedPresentation
Academy 2025 Boston: Clinical Confirmation of Optimal Pupil Size for Miotic Treatment of Presbyopia
presbyopiasource ↗
◆Oral PresentationVIZZApprovedPresentation
Academy 2025 Boston: Efficacy and Performance Measures for Presbyopia Treatment with Aceclidine 1.44% Ophthalmic Solution
presbyopiasource ↗
▲Product LaunchVIZZApprovedPost-Market
Commercial product shipments to consumers initiated in October
presbyopiasource ↗
Past FDA Catalysts and PDUFA Decisions
How LENZ actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-31 | VIZZ (aceclidine ophthalmic solution) 1.44% | NDA Submission | NDA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D31 / 100
Pipeline Score
$9M
Pipeline Value
$22M
Commercial Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 66%
Micro Cap(rank 436 of 660)
Percentile Rank
LENZ Therapeutics, Inc. faces pipeline headwinds (31/100), with $246M risk-adjusted pipeline value, led by GB-102 in Neovascular Age-Related Macular Degeneration (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $21.5M x 1.0 = $22M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| VIZZ | $5M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GB-102 Small moleculeCompletedNCT03249740 | Neovascular Age-Related Macular Degeneration | Phase 2 | COMPLETED | 88 | Jan 16, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every LENZ program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| LNZ100 | presbyopia | Phase 3 | 2024-10-27 | 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment; 69% of participants showing improvement within 30 minutes; 91% of participants indicated they noticed an improvement in their near vision; 84% and 69% achieved two-lines and three-lines or greater improvement at 30 minutes respectively; 88% and 74% achieved two-lines and three-lines or greater improvement at 3 hours respectively; 61% and 30% achieved two-lines and three-lines or greater improvement at 10 hours respectivelyRead More | CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement aRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| George Jeffrey P.Director | Buy | 5,592 5,592 held | $8.92 | 03/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LENZ
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.2 % (-50 %) | 23.73 M | 4.18 M |
LENZ Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LENZ ranks across every disease it competes in
Competitive Position is a premium feature
See how LENZ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLENZ News
LENZLENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
LENZ Therapeutics reported a total revenue of $5.5 million for Q2 2026, driven by VIZZ product sales and licensing agreements. The company noted strong patient persistence, with over 60% of patients purchasing multiple packs. A telehealth channel was launched to enhance access to VIZZ, and several international partnerships were established to expand its commercialization strategy. However, LENZ also faced a net loss of $31.9 million during the quarter.
Read more →LENZLENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
LENZ Therapeutics will host a webcast on August 11, 2026, to discuss its second quarter financial results and corporate highlights. The company is known for its FDA-approved aceclidine ophthalmic solution, VIZZ, which treats presbyopia. This event allows stakeholders to gain insights into the company's performance and future plans.
Read more →LENZLENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
LENZ Therapeutics has launched a telehealth prescribing option for its eye drop VIZZ, aimed at improving access for patients with presbyopia. This new platform allows for online evaluations by licensed eye care providers and includes home delivery of prescriptions. The initiative is supported by a national advertising campaign featuring Sarah Jessica Parker to increase awareness and adoption of VIZZ.
Read more →LENZLENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
LENZ Therapeutics has entered an exclusive license and commercialization agreement with Arrotex Pharmaceuticals for VIZZ, an FDA-approved treatment for presbyopia, in Australia and New Zealand. This partnership marks LENZ's fifth international collaboration for VIZZ, aiming to enhance patient access to this innovative therapy. The agreement includes an upfront payment and profit-sharing from sales.
Read more →LENZLENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ (LNZ100) in Greater China
LENZ Therapeutics has partnered with Everest Medicines, which acquired the rights to develop and commercialize VIZZ (LNZ100) in Greater China. This ophthalmic solution is designed to treat presbyopia and will be marketed following its New Drug Application, submitted in September 2025, with approval expected in early 2027. LENZ stands to gain up to $85 million in milestone payments along with royalties on sales. Everest Medicines aims to address significant unmet needs in the presbyopia treatment market with this acquisition.
Read more →LENZLENZ Therapeutics to Participate in Upcoming Investor Conferences
LENZ Therapeutics announced its participation in several upcoming investor conferences, including the William Blair Annual Growth Stock Conference, the Jefferies Global Healthcare Conference, and the Goldman Sachs Global Healthcare Conference. The company is focused on the commercialization of VIZZ, the first FDA-approved aceclidine-based eye drop for presbyopia. This product targets a large market, with millions affected by the condition.
Read more →LENZLENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
LENZ Therapeutics reported a total revenue of $1.9 million for the first quarter of 2026, driven largely by sales of its product VIZZ. The company has expanded its sales force and launched a direct-to-consumer advertising campaign featuring Sarah Jessica Parker, which has led to increased consumer engagement. Despite strong product uptake, LENZ reported a net loss of $41.5 million, reflecting significant expenses related to marketing and the expansion of operations. The management aims to enhance ECP integration of VIZZ and build a robust consumer market for the treatment of presbyopia.
Read more →LENZLENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference
LENZ Therapeutics will report its first quarter 2026 financial results on May 11, 2026, during a webcast. The company is known for its FDA-approved aceclidine ophthalmic solution, VIZZ, which treats presbyopia. Additionally, management will participate in one-on-one meetings at the Bank of America Global Healthcare Conference in Las Vegas from May 13-14, 2026.
Read more →LENZ▼ -8.4%on this news
LENZ Therapeutics, Inc. Investigated by the Portnoy Law Firm
LENZ Therapeutics, Inc. is being investigated by the Portnoy Law Firm for possible securities fraud after a significant drop in stock price. On December 12, 2025, the company's stock plummeted by 25.96% to $18.14 per share, largely due to adverse safety data regarding its VIZZ eye drop. Reports of a retinal tear linked to the product raised safety concerns, triggering a loss of investor confidence and highlighting the risks associated with the product. The law firm is seeking investors who wish to pursue claims related to these developments.
Read more →LENZLENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ for the Treatment of Presbyopia in the United Kingdom
LENZ Therapeutics has submitted a Marketing Authorization Application (MAA) for VIZZ to the UK’s MHRA, following its FDA approval in July 2025. VIZZ is the first aceclidine-based eye drop for treating presbyopia, aimed at improving near vision for adults. The submission marks the company's commitment to international expansion, backed by data from three successful Phase 3 trials in the U.S. These trials demonstrated rapid vision improvement and highlighted VIZZ's tolerability.
Read more →LENZ▼ -17.9%on this news
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
LENZ Therapeutics reported strong financial results for Q4 2025, with $1.6 million in revenues from its newly launched product VIZZ for presbyopia. The company has seen significant prescriber adoption and consumer engagement through marketing efforts. Despite a notable net loss, management remains optimistic about VIZZ's market potential and plans to expand its sales force and marketing strategies.
Read more →LENZ▲ +6.5%on this news
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
LENZ Therapeutics will host a webcast on March 24, 2026, to report its fourth quarter and full year 2025 financial results. The company is known for VIZZ, the first FDA-approved aceclidine-based eye drop for presbyopia. This event reflects the company's commitment to transparency and ongoing corporate updates.
Read more →LENZLENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of Presbyopia
LENZ Therapeutics has submitted a Marketing Authorization Application to the European Medicines Agency for VIZZ, the first aceclidine-based eye drop for treating presbyopia. This application follows previous submissions, underscoring the company's strategy to expand VIZZ's global reach. Phase 3 studies have shown positive results in improving near vision with excellent safety tolerability. If approved, VIZZ could significantly impact millions of Europeans suffering from age-related vision issues.
Read more →LENZLENZ Therapeutics to Present at Upcoming Investor Conferences
LENZ Therapeutics will present at two upcoming investor conferences in March 2026. The TD Cowen 46th Annual Health Care Conference will take place on March 2 in Boston, followed by the Leerink Partners 2026 Global Healthcare Conference on March 10 in Miami. The company focuses on its FDA-approved eye drop, VIZZ, for treating presbyopia.
Read more →LENZ▲ +12%on this news
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
LENZ Therapeutics has launched the 'Make it VIZZable' campaign featuring Sarah Jessica Parker, promoting VIZZ, a once-daily eye drop aimed at treating age-related blurry near vision. The campaign showcases Parker's personal experiences with presbyopia and emphasizes the convenience of using VIZZ over traditional reading glasses. Clinical trials indicate that VIZZ can significantly improve near vision for up to 10 hours.
Read more →LENZLENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
LENZ Therapeutics has reported preliminary unaudited financial results for Q4 2025, highlighting a successful launch of its eye drop product, VIZZ, for presbyopia. The company achieved approximately $1.6 million in net revenue and filled over 20,000 prescriptions within the first quarter of the product's launch. Additionally, the company has entered a partnership for VIZZ's commercialization in the Middle East, signaling its intention to expand internationally. Overall, the report reflects strong early market acceptance and growth potential for VIZZ.
Read more →LENZLENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
LENZ Therapeutics has partnered with Lunatus for the exclusive commercialization of VIZZ, an FDA-approved eye drop for presbyopia, in the Middle East. This partnership allows Lunatus to manage distribution across several countries, including the UAE and Saudi Arabia. LENZ will benefit from milestone payments and revenue sharing as they expand their market presence.
Read more →LENZLENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
LENZ Therapeutics has announced the submission of a New Drug Application for its product VIZZ™ (aceclidine ophthalmic solution) to the Ministry of Food and Drug Safety in South Korea. The application is supported by successful Phase 3 clinical trial results, showing significant improvements in near vision for presbyopic patients. Under a licensing agreement with Lotus Pharmaceutical, LENZ stands to gain substantial financial benefits from regulatory and commercial milestones. However, the product may cause mild side effects, which are typical for such treatments.
Read more →LENZ▼ -23.5%on this news
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
LENZ Therapeutics announced the FDA approval of VIZZ, the first aceclidine-based eye drop for presbyopia. The product launched commercially in October 2025, with over 2,500 eye care professionals prescribing it. The company reported a net loss of $16.7 million for Q3 2025, while also partnering with Sarah Jessica Parker for a marketing campaign set to launch in Q1 2026.
Read more →About LENZ Therapeutics, Inc.
Headquarters201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA, 92075
BIOPHARMAWATCH ELITE PLUS
Trade the next LENZ catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime